Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up [Yahoo! Finance]
Tempus AI, Inc. - Class A (TEM)
Company Research
Source: Yahoo! Finance
Execution on mix, reimbursement and bookings sets a clearer path to operating leverage. With Selectivity warranted near catalysts, investors weigh growth durability against GAAP losses and conversion timing of multi-year data deals. Third-quarter 2025 revenues rose 84.7% year over year to $334.2 million. Genomics climbed 117% to $252.9 million while Data and services increased 26.1% to $81.3 million. Tempus AI delivered 217,000 clinical tests, up 33% year over year on stronger oncology and hereditary demand. Oncology testing revenue reached $139.5 million and hereditary testing was $102.6 million. Within Data and services, the Insights sub-segment grew 37.6%, reflecting rising data licensing and study activity. Gross profit soared 98% to $209.9 million on higher volume and improving average selling prices. Adjusted EBITDA turned positive at $1.5 million, a sharp improvement from a year-ago loss, though GAAP net loss remained substantial at $80.0 million. Management emphasized co
Show less
Read more
Impact Snapshot
Event Time:
TEM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEM alerts
High impacting Tempus AI, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
TEM
News
- Tempus AI (NASDAQ:TEM) had its price target lowered by analysts at JPMorgan Chase & Co. from $85.00 to $80.00. They now have a "neutral" rating on the stock.MarketBeat
- Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer SymposiumBusiness Wire
- Tempus AI, Inc. (TEM): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Tempus AI (NASDAQ:TEM) was given a new $85.00 price target on by analysts at Morgan Stanley.MarketBeat
TEM
Earnings
- 11/4/25 - Beat
TEM
Sec Filings
- 12/16/25 - Form 144
- 12/12/25 - Form 4
- 12/11/25 - Form 144
- TEM's page on the SEC website